Tirzepatide reduced glycated hemoglobin by up to 2.5% and body weight by more than 20% across clinical trials, while improving cardiovascular risk factors and outcomes in HFpEF and OSA.
Does tirzepatide improve glycemic control, body weight, and cardiovascular risk factors in patients with type 2 diabetes mellitus, obesity, and related comorbidities?
Tirzepatide is a promising dual incretin therapy that significantly reduces HbA1c and body weight while offering cardioprotective benefits in patients with T2DM, obesity, HFpEF, and OSA.
Tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, represents a new class of incretin-based therapy for type 2 diabetes mellitus (T2DM), obesity, and related comorbidities. This narrative review synthesizes evidence from the SURPASS, SURMOUNT, and SUMMIT clinical trial programs. Across studies, tirzepatide reduced glycated hemoglobin (HbA1c) by up to 2.5% and body weight by more than 20%. It also improved cardiovascular risk factors (blood pressure, lipids, inflammation) and has demonstrated benefits in patients with heart failure with preserved ejection fraction (HFpEF) and obstructive sleep apnea (OSA), with reductions in the apnea-hypopnea index (AHI) and heart failure hospitalizations. Its safety profile is consistent with that of GLP-1 receptor agonists (GLP-1 RAs), although gastrointestinal side effects, gallbladder events, and thyroid cancer signals warrant monitoring. Ethical concerns related to off-label use, weight regain after discontinuation, and barriers to real-world access remain active issues. Ongoing outcome trials and real-world data will clarify its long-term role and potential integration into future clinical guidelines.
Thiriveedi et al. (Wed,) conducted a review in Type 2 diabetes mellitus, obesity, and related comorbidities (HFpEF, OSA). Tirzepatide was evaluated. Tirzepatide reduced glycated hemoglobin by up to 2.5% and body weight by more than 20% across clinical trials, while improving cardiovascular risk factors and outcomes in HFpEF and OSA.